upcoming glp-1 drugs What to Make of the Coverage and Cost Landscape Pharma Giants Bet on Next-Generation

FDA is requesting that the risk be removed from the warnings and precautions section of labeling for the GLP-1 obesity drugs Eli Lilly and Co.s Zepbound (tirzepatide) and Novo Nordisk A/S Saxenda (liraglutide) and Wegovy (semaglutide)

Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD randomized clinical trial

Clinical trials of GLP-1 receptor agonists have shown average reductions in daily energy intake of roughly 2030% during early treatment phases , reflecting the combined effects of increased satiety and reduced food preoccupation

Microdosing semaglutide is gaining popularity as individuals seek benefits beyond weight loss

Non-traditional routes of glucagon receptor pharmacology include the hepatic targeting of small molecules or nuclear hormones as is seen with the non-hyperglycemic glucagon-T3 conjugate [54]

doi: 10.1016/j.cmet.2016.04.006